Protalix

Amicus Therapeutics

This biotechnology company develops and delivers medicines to treat individuals living with rare metabolic conditions, specifically lysosomal storage disorders such as Fabry and Pompe disease.

Promedior

This biotechnology company develops drug therapies to treat rare fibrotic diseases for patients with conditions such as idiopathic pulmonary fibrosis and myelofibrosis.

EdiTy Therapeutics

This company develops immune cell delivery platforms to transport therapeutic proteins into diseased cells for patients with cancer and genetic disorders.

Protuoso Biosciences

This company develops multifunctional recombinant fusion proteins for pharmaceutical researchers and clinicians treating cardiometabolic, oncological and autoimmune diseases.

ProFactor Pharma

This company develops recombinant Factor VIII to treat haemophilia A in patients who currently lack access to affordable medication.

Pharos IBT

This company develops artificial intelligence platforms for discovering and developing treatments for rare and refractory diseases for the pharmaceutical and biotechnology industries.

GondolaBio

This biopharmaceutical company develops clinical-stage and preclinical medicinal therapeutics for patients living with rare genetic diseases.

Rocket Pharma

This company develops gene therapies for patients with rare and devastating genetic cardiovascular and haematological diseases.